Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at Wedbush from $42.00 to $43.00. They now have an "outperform" rating on the stock.
LowReport
Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at Wedbush from $42.00 to $43.00. They now have an "outperform" rating on the stock.
Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at HC Wainwright from $49.00 to $50.00. They now have a "buy" rating on the stock.
MediumReport
Tourmaline Bio, Inc. (NASDAQ: TRML) had its price target raised by analysts at HC Wainwright from $49.00 to $50.00. They now have a "buy" rating on the stock.
Tourmaline Bio, Inc. (NASDAQ: TRML) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $58.00 price target on the stock.
LowReport
Tourmaline Bio, Inc. (NASDAQ: TRML) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $58.00 price target on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: